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HEMOSTATIC FACTORS AND THE RISK OF MYOCARDIAL INFARCTION OR SUDDEN DEATH 
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Abstract
 
Background.
 
Increased levels of certain he-
mostatic factors may play a part in the development of
acute coronary syndromes and may be associated with
an increased risk of coronary events in patients with an-
gina pectoris.
 
Methods.
 
We conducted a prospective multicenter
study of 3043 patients with angina pectoris who under-
went coronary angiography and were followed for two
years. Base-line measurements included the concen-
trations of selected hemostatic factors indicative of a
thrombophilic state or endothelial injury. The results were
analyzed in relation to the subsequent incidence of myo-
cardial infarction or sudden coronary death.
 
Results.
 
After adjustment for the extent of coronary
artery disease and other risk factors, an increased inci-
dence of myocardial infarction or sudden death was as-
sociated with higher base-line concentrations of fibrino-
gen (mean 
 

 
SD, 3.28
 

 
0.74 g per liter in patients who
subsequently had coronary events, as compared with
3.00
 

 
0.71 g per liter in those who did not; P
 

 
0.01), von
Willebrand factor antigen (138
 

 
49 percent vs. 125
 

 
49
percent, P
 

 
0.05), and tissue plasminogen activator
(t-PA) antigen (11.9
 

 
4.7 ng per milliliter vs. 10.0
 

 
4.2 ng
per milliliter, P
 

 
0.02). The concentration of C-reactive
protein was also directly correlated with the incidence of
coronary events (P
 

 
0.05), except when we adjusted for
the fibrinogen concentration. In patients with high serum
cholesterol levels, the risk of coronary events rose with
increasing levels of fibrinogen and C-reactive protein,
but the risk remained low even given high serum choles-
terol levels in the presence of low fibrinogen concentra-
tions.
 
Conclusions.
 
In patients with angina pectoris, the lev-
els of fibrinogen, von Willebrand factor antigen, and t-PA
antigen are independent predictors of subsequent acute
coronary syndromes. In addition, low fibrinogen concen-
trations characterize patients at low risk for coronary
events despite increased serum cholesterol levels. Our
data are consistent with a pathogenetic role of impaired
fibrinolysis, endothelial-cell injury, and inflammatory activ-
ity in the progression of coronary artery disease. (N Engl
J Med 1995;332:635-41.)
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C
 
ORONARY thrombosis is now generally recog-
nized as the precipitating event in the transition
from stable to acute ischemic heart disease, manifested
by unstable angina,
 
1
 
 acute myocardial infarction,
 
2
 
 and
sudden death from coronary causes.
 
3
 
 Besides local
stimuli such as disruption of plaques, systemic throm-
bogenic factors may contribute to the occurrence, ex-
tent, and persistence of coronary thrombosis and its
clinical sequelae.
 
4
 
 These factors include abnormalities
of blood flow,
 
5
 
 platelet hyperreactivity,
 
6,7
 
 defective fi-
brinolysis,
 
8,9
 
 and increased concentrations of hemostat-
ic proteins, specifically fibrinogen and factor VII.
 
10
 
Thus, with the use of appropriate laboratory tests, it
may be possible to detect a thrombogenic state and
thus identify patients at increased risk for cardiovascu-
lar disease.
Support for this hypothesis comes mainly from pro-
spective studies of healthy subjects, which have demon-
strated a direct and independent association between
plasma fibrinogen concentrations and the risk of coro-
nary events.
 
5,10-14
 
 However, data on patients with known
coronary artery disease are sparse and come from
small cohort studies of patients with angina pectoris
 
15,16
 
or those who have had a first myocardial infarc-
tion.
 
8,9,17-19
 
In the European Concerted Action on Thrombosis
and Disabilities (ECAT) Angina Pectoris Study,
 
20
 
 we
recruited more than 3000 patients with angina pectoris
and used angiography to determine the extent of coro-
nary artery disease. Our principal objective was to in-
vestigate the associations between base-line measure-
ments of hemostatic factors that indicate the existence
of a thrombophilic state or an alteration in the vascular
endothelium, on the one hand, and the occurrence of
coronary events during a two-year follow-up period, on
the other.
 
M
 
ETHODS
 
Patients
 
Men and women who underwent coronary angiography because of
suspected coronary artery disease were eligible for the study. Patients
who had had a myocardial infarction within the preceding two
months or who had severe right-heart failure or noncardiac diseases
likely to cause death within one year were excluded. A total of 3043
patients from 18 European centers (listed in the Appendix) were re-
cruited between October 1984 and June 1987.
 
Blood Sampling and Measurements of Hemostatic 
Factors
 
The conditions of blood sampling and storage and the measure-
ment of hemostatic factors have been described in detail elsewhere.
 
21
 
The technicians were trained at the central laboratory, and an exter-
nal quality-assessment scheme was used to monitor their perform-
ance throughout the study.
 
22,23
 
The following tests were performed. The number and function of
platelets were assessed by means of whole-blood platelet counts and
measurements of 
 
b
 
-thromboglobulin and platelet factor 4. The state
of the coagulation system was assessed by measurements of the acti-
vated partial-thromboplastin time, fibrinogen, fibrinopeptide A, von
Willebrand factor antigen, factor VIII activity, antithrombin III
antigen and activity, and protein C antigen and activity. The fibri-
nolytic system was assessed by the measurement of plasminogen,
 
a
 
2
 
-antiplasmin activity, histidine-rich glycoprotein, and plasminogen-
activator inhibitor type 1 (PAI-1) antigen and activity. Tissue plas-
minogen activator (t-PA) antigen and activity, as well as the euglob-
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ulin clot-lysis time, were measured before and after 10 minutes of
venous occlusion.
The hematocrit, white-cell count, and ABO blood type were deter-
mined according to standard local procedures, as were the total cho-
lesterol and triglyceride concentrations. C-reactive protein was meas-
ured by a nephelometric method.
 
Coronary Angiography
 
Coronary angiography was performed, usually by the Judkins tech-
nique but occasionally by the Sones technique.
 
24
 
 For the purpose of
this study, the angiographic results were expressed as the number of
vessels (0 to 4) with stenosis of at least 50 percent of the vessel diam-
eter or occlusion.
 
Follow-up and Ascertainment of End Points
 
Patients were evaluated annually for two years, and information on
deaths, coronary events, hospital admissions, and current drug use
was obtained at each follow-up contact. Reported clinical events were
reviewed independently by an end-points committee whose members
were blinded to the results of the hemostatic tests. The primary end
points of the study were fatal or nonfatal myocardial infarction, de-
fined according to standard diagnostic criteria,
 
25
 
 and sudden death
from coronary causes, defined as death within one hour of the onset
of cardiac symptoms. Events occurring within 72 hours of surgery
(usually coronary-artery bypass surgery) or angioplasty were consid-
ered primarily related to the intervention. Patients with such events
were excluded from the analyses, as were patients with possible but
unconfirmed myocardial infarction or death from other cardiac caus-
es, other causes, or uncertain causes.
 
Statistical Analysis
 
To investigate the association between the concentrations of hemo-
static factors and the incidence of definite coronary events, we used
multiple regression analysis, with the hemostatic factor as the de-
pendent variable. Mean differences between the patients who had
events and those who were event-free were calculated after adjust-
ment for the medical center; the patient’s age, sex, and ABO blood
type; and any of the following base-line characteristics if they were
demonstrated to be significantly related (P
 

 
0.01) to the incidence of
events: drugs used at the time of blood sampling; previous myocar-
dial infarction; history of diabetes or hypertension; smoking; history
of chest pain, including the type of angina; extent of coronary artery
disease as assessed angiographically; left ventricular ejection fraction
and end-diastolic pressure; body-mass index (the weight in kilo-
grams divided by the square of the height in meters); blood pressure;
and total cholesterol and triglyceride concentrations. Hemostatic var-
iables were analyzed on a logarithmic scale when this transformation
produced a more symmetrical (gaussian) distribution.
A separate analysis was carried out of the association between oth-
er (nonhemostatic) factors and the risk of coronary events; for this
analysis we used multiple logistic-regression techniques and the
same variables listed above.
The P values given here for differences in laboratory-test results re-
flect adjusted data and are two-tailed. The standardized relative risk
was calculated as the relative risk of a coronary event for each in-
crease of 1 SD in a given variable.
 
26
 
R
 
ESULTS
 
Base-Line Characteristics
 
Of the 3043 patients enrolled in the study, 2960 (97
percent) were followed for two years. During this peri-
od 837 patients underwent coronary-artery bypass sur-
gery, 223 underwent coronary angioplasty, and 49
underwent both interventions. A total of 106 definite
coronary events were reported, 40 of which occurred in
patients undergoing bypass surgery or angioplasty ei-
ther just before or after the clinical event. An additional
154 major events did not fulfill the criteria for study
end points (Table 1).
The base-line characteristics of the 106 patients who
had definite coronary events and the 2700 patients in
the event-free group are summarized in Table 2. After
adjustment for medical center, sex, and age, when ap-
propriate, the patients who had coronary events were
older, tended to have more severe angina, and were
more likely to have a history of myocardial infarction
than those without such events. They also had more ex-
tensive coronary artery disease and were more likely to
have been treated with diuretic agents or digitalis.
These differences, along with other base-line factors,
were accounted for in the multiple regression analysis
of the associations between the concentrations of hemo-
static factors and the incidence of coronary events. A
detailed analysis of base-line clinical and laboratory
data was published earlier.
 
20
 
Concentrations of Hemostatic Factors and Other Test 
Results in Relation to Outcome
 
Among the various hemostatic variables measured,
only the levels of fibrinogen, von Willebrand factor an-
tigen, and t-PA antigen were significantly and directly
related to the incidence of coronary events, after ad-
justment for other confounding factors (Table 3).
Regression analyses indicated significant positive
correlations between the fibrinogen level and age
(P
 

 
0.001), the body-mass index (P
 

 
0.001), the extent
of coronary artery disease at enrollment (P
 

 
0.001),
and smoking status (P
 

 
0.003). In addition, the mean
fibrinogen concentrations were 7.6 percent, 5.8 per-
cent, and 4.3 percent higher in patients receiving hep-
arin, diuretics, and oral anticoagulants, respectively
(P
 

 
0.002 for all comparisons). After adjustment for
these confounding factors, fibrinogen concentrations
in the group with coronary events were on average
6.5  percent higher than those in the event-free group
(P
 

 
0.01).
Concentrations of von Willebrand factor antigen in-
creased with age (P
 

 
0.001) and were significantly
higher in the patients receiving diuretics, digitalis, hep-
arin, or oral anticoagulants than in those not receiving
these agents (P
 

 
0.01 for all comparisons). Patients
 
*These patients were excluded from subsequent analyses.
†Occurring within 72 hours of surgery or angioplasty.
 
Table 1. Study Population and Events during
Follow-up.
 
P
 
ATIENT
 
 C
 
ATEGORY
 
N
 
O
 
. (%)
 
Patients enrolled 3043 
Patients with complete two-year follow-up 2960 (97.3)
Patients with definite coronary events 106 (3.6)
Sudden coronary death 31
Fatal myocardial infarction 9 
Nonfatal myocardial infarction 66 
Patients with other major events* 154 (5.2)
Possible myocardial infarction (not confirmed) 24 
Events related to interventions†
Death 44 
Nonfatal myocardial infarction 37 
Death from other cardiac causes 13 
Death from cancer 7 
Death from other uncertain causes 29 
Patients without events 2700 (91.2)
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with blood type O had substantially lower mean con-
centrations of von Willebrand factor antigen (107 per-
cent) than patients in blood group A (140 percent),
B (150 percent), or AB (146 percent) (P
 

 
0.001 for all
comparisons). After adjustment for these variables, the
concentration of von Willebrand factor antigen was on
average 8.5 percent higher in the patients who subse-
quently had coronary events than in those who did not
(P
 

 
0.05).
Among the fibrinolytic factors, the level of t-PA anti-
gen, measured before venous occlusion, was significant-
ly higher in the patients who subsequently had coro-
nary events; the mean difference between the groups
was 10.2 percent (P
 

 
0.02) after adjustment for the
confounding influence of age, sex, medications (hepa-
rin and diuretics), smoking status, body-mass index,
triglyceride concentrations, extent of coronary artery
disease, and ejection fraction. Concentrations of t-PA
antigen were directly correlated with both PAI-1 activ-
ity and PAI-1 antigen (r
 

 
0.40 and r
 

 
0.47, respective-
ly; P
 

 
0.001 for both comparisons). However, neither
PAI-1 antigen and activity nor the ratio of PAI-1 anti-
gen to t-PA antigen differed significantly between the
group with coronary events and the event-free group
when all confounding factors were adjusted for (P
 

 
0.2
for all comparisons).
The concentrations of C-reactive protein were on av-
erage 20.2 percent higher in the patients who had
coronary events than in those without such events
(P
 

 
0.05), after adjustment for smoking status, body-
mass index, ejection fraction, extent of coronary ar-
tery disease, triglyceride concentrations, and use of
diuretics, digitalis, and heparin. The base-line meas-
urements of C-reactive protein and fibrinogen, both
of which are known to be hepatic acute-phase pro-
teins,
 
27-29
 
 were strongly correlated (r
 

 
0.49; P
 

 
0.001).
The association of fibrinogen concentrations with the
risk of coronary events remained statistically signifi-
cant (P
 

 
0.013) after adjustment for the C-reactive
protein concentration, whereas the relation of the con-
centration of C-reactive protein to the risk of coronary
events was no longer significant after adjustment for
the fibrinogen concentration (P
 

 
0.48).
 
Prediction of the Risk of Coronary Events
 
Table 4 shows the relative risk of definite coronary
events in five equal subgroups of the patient population
defined according to the distributions of laboratory var-
iables that were independently related to the incidence
of coronary events. Whereas fibrinogen was associated
with a threefold increase in risk from the lowest to the
highest quintile group, a 1.5- to 2-fold increase in risk
was observed with increasing levels of each of three
factors: von Willebrand factor antigen, t-PA antigen,
and C-reactive protein.
A history of myocardial infarction was associated
with a 1.6-fold increase in the risk of coronary events
(P
 

 
0.04) but did not significantly influence the rela-
tion of the variables mentioned above to the incidence
of coronary events. Furthermore, the standardized rel-
ative risks shown in Table 4 did not differ significantly
among patients with stable angina on exertion, those
with unstable angina, and those who had angina with-
 
*P values for the comparison of patients with events and event-free patients were obtained
as follows: for sex, by the chi-square test for association, with stratification by center and age
group; for age by comparison of mean ages with adjustment for medical center and sex; for
type of angina, history of myocardial infarction, extent of coronary artery disease, smoking,
and medications, by the chi-square test for association, with stratification by center, sex, and
age group.
†Percentages have been calculated as a proportion of those with known values. Because of
rounding, percentages do not always total 100.
‡Either worsening of angina within the previous four weeks or angina at rest.
§More than two months before enrollment.
¶A reduction of at least 50 percent of the vessel diameter. Data were missing for one patient
with a coronary event and for eight in the event-free group.
 

 
Includes some patients with stenosis of the left main coronary artery.
**Data were missing for three patients in the event-free group.
††Values for protein C and activated partial-thromboplastin time were considered unknown
for patients receiving oral anticoagulants at the time of blood sampling.
 
Table 2. Base-Line Characteristics of the Patients with and with-
out Coronary Events.
 
C
 
HARACTERISTIC
 
G
 
ROUP
 
 
 
WITH
 
 E
 
VENTS
 
 
(N
 

 
106)
E
 
VENT
 
-
 
FREE
 
 G
 
ROUP
 
 
(N
 

 
2700) P V
 
ALUE
 
*
 
no. (%)
 
†
 
Sex 0.18
Male 95 (90) 2296 (85)
Female 11 (10) 404 (15)
Age (yr) 0.02
 

 
45 13 (12) 292 (11)
45–69 83 (78) 2300 (85)
 

 
69 10 (9) 108 (4)
Type of angina 0.06
Unstable angina‡ 61 (58) 1285 (48)
Stable angina on exertion 38 (36) 988 (37)
Angina without typical
chest pain
7 (7) 404 (15)
Previous myocardial infarction§ 71 (67) 1173 (43)
 

 
0.001
No. of stenosed coronary
arteries¶
 

 
0.001
1 Vessel 19 (18) 706 (26)
2 Vessels 35 (33) 652 (24)
3 or 4 Vessels
 

 
46 (44) 668 (25)
None 5 (5) 666 (25)
Smoking status** 0.60
Current smoker 25 (24) 531 (20)
Ex-smoker 57 (54) 1392 (52)
Nonsmoker 24 (23) 774 (29)
Medications
Antiplatelet drugs (mainly
aspirin)
34 (32) 677 (25) 0.08
Heparin 11 (10) 161 (6) 0.28
Oral anticoagulants†† 16 (15) 398 (15) 0.96
 
b
 
-adrenoceptor blockers 39 (37) 975 (36) 0.61
Calcium antagonists 73 (69) 1792 (66) 0.59
Nitrates 77 (73) 1742 (65) 0.11
Diuretics 34 (32) 479 (18)
 

 
0.001
Digitalis 19 (18) 267 (10) 0.001
 
*Values are means 
 

 
SD, with adjustment for medical center, age, and sex. P values have
also been adjusted for all the other risk factors for coronary disease on which we obtained data
(see the Methods section). For statistical analyses of logarithmically transformed values, ge-
ometric means and approximate standard deviations are shown. Percentages have been calcu-
lated on the basis of the numbers with known values. The number of patients with definite cor-
onary events included in the statistical analyses ranged from 89 to 106 for the various
laboratory tests.
 
Table 3. Laboratory-Test Results According to Outcome.
 
*
 
V
 
ARIABLE
 
G
 
ROUP
 
 
 
WITH
 
 E
 
VENTS
 
 
(N
 

 
106)
E
 
VENT
 
-
 
FREE
 
 G
 
ROUP
 
 
(N
 

 
2700) P V
 
ALUE
 
Fibrinogen (g/liter) 3.28
 

 
0.74 3.00
 

 
0.71 0.01
Von Willebrand factor antigen (%) 137.5
 

 
48.8 124.6
 

 
49.1 0.05
t-PA antigen before venous 
occlusion (ng/ml)
11.94.7 10.04.2 0.02
C-reactive protein (mg/liter) 2.151.96 1.611.38 0.05
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out typical chest pain (for example, acute left abdomi-
nal pain, anxiety, or dyspnea).
Higher left ventricular end-diastolic pressures meas-
ured at base line were associated with a 20 percent
increase in the risk of coronary events for each addi-
tional 5 mm Hg of pressure (P0.02). In addition,
patients who were receiving diuretics when they en-
tered the study had a 2.5-fold risk of subsequent cor-
onary events (P0.001), an increase that probably
reflects the poor prognosis of patients with heart fail-
ure. Finally, patients in blood groups A and B had 1.6
times the risk of coronary events of patients with blood
type O (P0.05). Significant associations with these
base-line characteristics were taken into account in our
analysis of the relation of hemostatic factors and oth-
er laboratory measurements to the risk of coronary
events.
As expected, the extent of coronary artery disease
was the single most powerful predictor of coronary
events (Table 5). However, despite the correlation be-
tween the concentrations of fibrinogen, t-PA antigen,
and C-reactive protein and the extent of coronary
disease,20 these variables remained independently pre-
dictive of subsequent coronary events and were val-
uable in identifying patients at low and at high risk
of such events regardless of the severity of coronary
disease.
Serum total cholesterol concentrations were not in-
dependently related to the risk of coronary events in
this group of patients; the mean serum cholesterol con-
centration was 257 mg per deciliter (6.66 mmol per li-
ter) in patients who subsequently had coronary events,
as compared with 246 mg per deciliter (6.37 mmol per
liter) in the event-free group after adjustment for other
coronary risk factors (P0.33). However, when we an-
alyzed the combined influence of fibrinogen, C-reactive
protein, and total cholesterol on the risk of coronary
events, it was clear that high fibrinogen concentra-
tions, and particularly the combination of high fibrino-
gen concentrations with high concentrations of C-reac-
tive protein, added markedly to the association of
increased risk with high total cholesterol concentra-
tions (Fig. 1). Conversely, patients with low concentra-
tions of both fibrinogen and C-reactive protein had a
low risk of coronary events even in the presence of high
total cholesterol concentrations.
DISCUSSION
We designed this study to assess the prognostic value
of the extent of coronary artery disease and of selected
hemostatic variables in patients with angina pectoris
who were undergoing coronary angiography. Three he-
mostatic variables — namely, the concentrations of
fibrinogen, von Willebrand factor antigen, and t-PA
antigen — proved to be directly and independently cor-
related with the risk of subsequent coronary events. We
also found an association between the risk of coronary
events and the concentration of acute-phase reactant
C-reactive protein.
Not surprisingly, the extent of coronary artery dis-
ease assessed by angiography at study entry was the
single most important indicator of outcome. It was pos-
itively related to the plasma concentrations of fibrino-
gen, t-PA antigen, and C-reactive protein, but even
after adjustment for the extent of coronary artery dis-
ease, these variables remained independently associat-
ed with the risk of coronary events, and they were valu-
able in identifying patients at low and at high risk
within each category of disease severity. Moreover, the
predictive value of these factors did not seem to depend
on the type of angina at the base-line examination.
Indeed, in this study,20 although not in others,30-33 the
type of angina was unrelated to the results of hemo-
static tests and measurements of C-reactive protein.
Hence, these variables appear to be independent mark-
ers of coronary atherosclerosis that is likely to progress
to atherothrombotic vessel occlusion in patients with
symptomatic angina pectoris.
A strong association with the risk of subsequent
coronary events was observed for the fibrinogen con-
centration; the risk tripled from that for the patients in
the bottom fifth of the sample in terms of fibrinogen
levels to that for those in the top fifth. The strength of
this association in our patients with angina pectoris is
similar in magnitude to that in healthy subjects.10-14
Thus, on the basis of the available evidence, an in-
creased fibrinogen concentration — even within the
normal range — can be regarded as a strong and in-
dependent predictor of cardiovascular risk not only in
apparently healthy people, but also in patients with
manifest coronary artery disease.
*The relative risks are shown for each of five equal groups (quintiles) of subjects defined
according to the concentrations of each factor, from 1 (the group with the lowest concentra-
tions) to 5 (the group with the highest). Relative risks have been adjusted for all confounding
factors (see the Methods section). The group of patients with the lowest values for each factor
serves as the reference group.
†Defined as the relative risk for each increase of 1 SD in the variable in question. CI denotes
confidence interval.
Table 4. Relative Risk of Coronary Events According to the Con-
centrations of Hemostatic Factors.*
VARIABLE QUINTILE
STANDARDIZED RELATIVE
RISK (95% CI)†
1 2 3 4 5
Fibrinogen 1.0 1.89 2.33 2.56 2.89 1.31 (1.07–1.61)
Von Willebrand 
factor antigen
1.0 1.23 1.39 1.46 1.85 1.24 (1.00–1.53)
t-PA antigen 1.0 1.64 1.64 1.73 2.10 1.29 (1.04–1.60)
C-reactive protein 1.0 1.07 1.14 1.57 1.57 1.24 (1.00–1.55)
*The risk as compared with that among patients with 50 per-
cent stenosis, after adjustment for medical center, age, and other
coronary risk factors (see the Methods section). P0.001 for the
differences between categories. CI denotes confidence interval.
Table 5. Relative Risk of Coronary Events
According to Angiographic Status
at Base Line.*
NO. OF CORONARY ARTERIES
WITH 50 PERCENT STENOSIS
RELATIVE RISK
(95% CI)
0 1
1 3.44 (0.98–12.1)
2 7.55 (2.23–25.7)
3 or 4 8.14 (2.41–27.5)
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Our findings regarding the prognostic value of the
concentrations of von Willebrand factor antigen extend
recent observations in smaller cohorts of patients with
stable angina or those who had had myocardial infarc-
tions.15,18 Increased plasma concentrations of von Wil-
lebrand factor derived from endothelial cells have been
reported in various vascular disorders.34 Thus, increas-
es in the concentration of this factor in patients at high
risk for coronary thrombotic occlusion may reflect en-
dothelial perturbation.
The association we found between the concentration
of t-PA antigen and the risk of coronary events accords
with the results of recent prospective studies in patients
with severe angina pectoris16 and in healthy men35;
these studies also identified t-PA antigen as a marker
of cardiovascular risk. The significant positive correla-
tions between t-PA antigen and plasma PAI-1 antigen
and activity in our study and that of others36 suggest
that increased concentrations of t-PA antigen in large
part reflect circulating t-PA–PAI-1 complex and thus
indicate reduced rather than enhanced fibrinolytic ac-
tivity. Irrespective of these considerations, increased
synthesis of t-PA antigen by endothelial cells may indi-
cate dysfunction of these cells.
Increased concentrations of C-reactive protein have
been reported in patients with acute coronary syn-
dromes33,37,38 and predict poor outcomes in patients
with severe unstable angina.39 Their relevance in pa-
tients with other types of angina and their long-term
prognostic value with respect to cardiovascular risk
have been unclear, however. The positive association of
increasing concentrations of C-reactive protein with in-
creases in the risk of coronary events in our study sug-
gests a possible role of inflammation in the progression
of coronary artery disease. This process may account,
in part, for the association of risk with the concentra-
tion of fibrinogen, which is also known to act as a he-
patic acute-phase protein.29
An interesting new aspect of our results is the effect
of fibrinogen concentrations, either alone or in combi-
nation with those of C-reactive protein, on the risk of
coronary events even within subgroups of patients de-
fined by serum cholesterol level. High concentrations of
fibrinogen and C-reactive protein could be used to
identify patients with hypercholesterolemia who are at
particularly high risk for coronary events. In contrast,
low fibrinogen concentrations were associated with a
low risk of new coronary events even in patients with
high serum cholesterol levels. Similarly, healthy sub-
jects with high serum levels of low-density lipoprotein
cholesterol and low fibrinogen concentrations have a
lower risk of coronary events than similar subjects with
high fibrinogen concentrations.14 These findings have
implications for risk-factor control and should be con-
sidered in the design of future interventional trials.
Our results highlight the role of the concentrations
of fibrinogen, t-PA antigen, and von Willebrand factor
antigen as independent predictors of cardiovascular
risk in patients with coronary artery disease. The asso-
ciation of higher concentrations of both fibrinogen and
C-reactive protein with increased coronary risk sug-
gests that the fibrinogen concentration becomes elevat-
ed, at least in part, as a consequence of inflammatory
reactions that occur in progressive atherosclerosis. The
positive association of the risk of coronary events with
the concentrations of t-PA antigen and von Willebrand
factor antigen, both of which are released by endothe-
lial cells, points to possible endothelial perturbation in
patients prone to coronary atherothrombosis.
Figure 1. Incidence of Coronary Events during Two Years of Fol-
low-up, According to Concentrations of Fibrinogen, C-Reactive
Protein, and Total Cholesterol.
Panel A shows the risk of coronary events according to fibrino-
gen and total cholesterol concentrations. Panel B shows the risk
according to fibrinogen and C-reactive protein concentrations
combined, as compared with total cholesterol concentrations.
The concentrations of these variables are divided into three cat-
egories (lower, middle, and higher), each containing a third of the
sample, according to their respective distributions. In Panel B,
“intermediate” refers to all combinations of fibrinogen and C-reac-
tive protein concentrations other than lower–lower or higher–
higher. The values used to divide the sample into thirds were
2.71 and 3.31 g per liter for fibrinogen, 5.79 and 6.80 mmol per
liter (224 and 263 mg per deciliter) for cholesterol, and 0.88 and
2.17 mg per liter for C-reactive protein. The number of coronary
events and the number of patients at risk are shown for each
group. Only patients for whom data on both fibrinogen and total
cholesterol concentrations were available are included
in the analysis.
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APPENDIX
The following institutions and investigators participated in the
ECAT study of the Commission of the European Communities. Par-
ticipating centers are listed in descending order of the number of pa-
tients enrolled, with the number of patients and the responsible in-
vestigators in parentheses: Bordeaux, France (341) — Hôpital
Cardiologique, Clinique Medicale Cardiologique (H. Bricaud) and
Laboratoire d’Hémobiologie (M.R. Boisseau); Lyon, France (325) —
Hôpital Cardiovasculaire et Pneumologique Louis Pradel ( J.B. Dela-
haye) and Faculté de Medicine Alexis Carrel, Laboratoire d’Hémo-
biologie (M. Dechavanne); Münster, Germany (319) — University De-
partments of Cardiology (U.S. Müller) and Haematology (U.
Schmitz-Huebner); Bad Rothenfelde, Germany (288) — Schüchter-
mann-Klinik, Department of Cardiology (R. Buchwalsky and J. Kie-
nast, Münster); Basel, Switzerland (235) — Kantonsspital, University
Department of Cardiology (F. Burkart) and Haemostasis Laboratory
(F. Duckert); Vienna, Austria (208) — I. University Department of
Medicine (G. Kronik and H. Niessner); Athens, Greece (162) —
NIMTS Hospital, Department of Cardiology (C.D. Michalopoulos),
Alexandra Hospital, Department of Clinical Therapeutics (S.D.
Moulopoulos), and Laikon General Hospital, Blood Transfusion
Center (T. Mandalaki); Frankfurt, Germany (156) — University Center
for Internal Medicine, Departments of Cardiology (W.D. Bussmann)
and Angiology (K. Breddin); Giessen, Germany (144) — University De-
partment for Internal Medicine (B. Wüsten and F.R. Matthias); Paris
(132) — Hôpital Broussais, Clinique Cardiologique (L. Guize), and
Hôtel-Dieu, Laboratoire Central d’Hématologie (M.M. Samama);
Bern, Switzerland (128) — Inselspital, University Department of Med-
icine (H.P. Gurtner and P.W. Straub); Pisa, Italy (118) — Centro Na-
zionale di Ricerca Institute of Clinical Physiology (A. L’Abbate and
R. de Catarina); Brussels, Belgium (114) — Clinique Universitaire St.
Luc, Department of Cardiology (F. Lavenne), and University of Lou-
vain, Laboratory for Haemostasis and Thrombosis Research (R. Ma-
sure); Leeds, United Kingdom (84) — General Infirmary, Departments
of Cardiology (D.R. Smith) and Medicine (C.R.M. Prentice); Nau-
heim, Germany (82) — Kerckhoff-Clinic (M. Schlepper) and Max
Planck Gesellschaft Research Group for Blood Coagulation and
Thrombosis (G. Müller-Berghaus); Mannheim, Germany (80) — I. Uni-
versity Department of Medicine (B. Stegaru and W. Kirschstein);
Marseille, France (67) — C.H.U. Timone, Department of Cardiology
(A. Serradimigni), and Laboratoire d’Hématologie (I. Juhan-Vague);
and Eindhoven, the Netherlands (60) — Catharina Hospital, Depart-
ments of Cardiology ( J.J.R.M. Bonnier and H.R. Michels) and Hae-
matology ( J.J.M.L. Hoffmann).
The members of the study committees and the principal investiga-
tors of the reference laboratories were as follows: ECAT Advisory
Board: E.F. Lüscher (chairman), Bern; J.P. Boissel, Lyon; P. Brakman,
Leiden, the Netherlands; D.G. Julian, London; C.R.M. Prentice,
Leeds; M. Verstraete, Leuven, Belgium; ECAT project leader: F. Haver-
kate, Leiden; Protocol Advisory Board: H. Bricaud, Bordeaux; F. Duck-
ert, Basel; P.G. Hugenholtz, Rotterdam, the Netherlands; D. Julian,
London; J. Lubsen, Rotterdam; U.S. Müller, Münster; C.R.M. Pren-
tice, Leeds; S.G. Thompson, London; and J. van de Loo, Münster;
Statistical Center: S.G. Thompson and S.D.M. Pyke, London; End Point
Committee: G. Breithardt, Münster; M. Brochier, Tours, France; and
H. Tunstall-Pedoe, Dundee, United Kingdom; Reference Laboratories:
R.M. Bertina, Leiden (protein C); J. Conard, Paris (histidine-rich
glycoprotein); F. Duckert, Basel (antithrombin III, factor VIII, von
Willebrand factor, fibrinogen); P.J. Gaffney, London (plasminogen);
D.S. Pepper, Edinburgh, United Kingdom (platelet factor 4 and
b-thromboglobulin); L. Petersen, Hvidovre, Denmark (alpha2-anti-
plasmin); L. Poller, Manchester, United Kingdom (activated partial-
thromboplastin time); F.E. Preston, Sheffield, United Kingdom
(euglobulin clot-lysis time); P.W. Straub, Bern (fibrinopeptide A);
J. Verheijen, Leiden (t-PA activity); I. Juhan-Vague, Marseille (t-PA
antigen); E. Kruithof, Lausanne, Switzerland (PAI-1); Laboratory Assay
Committee: F. Duckert, Basel (chairman); J.J. Sixma, Utrecht, the Neth-
erlands; J. Jespersen, Esbjerg, Denmark; R.M. Bertina, Leiden; D.S.
Pepper, Edinburgh; L. Poller, Manchester; D.C. Rijken, Leiden; Central
Analysis: R.M. Bertina, Leiden (protein C activity); J. Jespersen, Esb-
jerg (PAI-1); I. Juhan-Vague, Marseille (t-PA antigen, C-reactive pro-
tein); and Executive Committee: F. Duckert, Basel; F. Haverkate, Leiden;
J. van de Loo, Münster (chairman); S.G. Thompson, London.
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